Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 362

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

New progestagens for contraceptive use

Sitruk-Ware, Regine·2006·Human Reproduction Update

Abstract

The progestins have different pharmacologic properties depending upon the parent molecule, usually testosterone or progesterone (P), from which they are derived. Very small structural changes in the parent molecule may induce considerable differences in the activity of the derivative. In hormonal contraceptives, progestins represent the major agent designed for suppressing ovulation and are used in combination with estrogen (E) usually ethinyl-estradiol (EE). The development of new generations of progestins with improved selectivity profiles has been a great challenge. Steroidal and nonsteroidal progesterone receptor (PR) agonists have been synthesized as well, although the latter are still in a very early stage of development. Several new progestins, have been synthesized in the last two decades. These include dienogest (DNG), drospirenone (DRSP), Nestorone (NES), nomegestrol acetate (NOMAc) and trimegestone (TMG). These new progestins have been designed to have no androgenic or estrogenic actions and to be closer in activity to the physiological hormone P. DRSP differs from the classic progestins as it is derived from spirolactone. It is essentially an antimineralocorticoid steroid with no androgenic effect but a partial antiandrogenic effect. The antiovulatory potency of the different progestins varies. TMG and NES are the most potent progestins synthesized to date, followed by two of the older progestins, keto-desogestrel (keto-DSG) and levonorgestrel (LNG). The new molecules TMG, DRSP and DNG also have antiandrogenic activity. Striking differences exist regarding the side effects among the progestins and the combination with EE leads to other reactions related to the E itself and whether the associated progestin counterbalances, more or less, the estrogenic action. The 19-norprogesterone molecules and the new molecules DRSP and DNG are not androgenic and, therefore, have no negative effect on the lipid profile. Given their pharmacological properties, it is likely that the new progestins may have neutral effects on metabolic or vascular risks. However, this hypothesis must be confirmed in large clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/humupd/dmi046

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Research works printed but not linked: 17

  1. Bouali, 2001, Gynecol Endocrinol, 15, 48, 10.1080/gye.15.1.48.55 · doi:10.1080/gye.15.1.48.55
  2. Catherino, 1993, Br J Cancer, 67, 945, 10.1038/bjc.1993.175 · doi:10.1038/bjc.1993.175
  3. Duc, 1995, Arzneimittelforschung, 45, 70
  4. Erkkola, 2005, Acta Obstet Gynecol Scand, 84, 207, 10.1111/j.0001-6349.2005.00759.x · doi:10.1111/j.0001-6349.2005.00759.x
  5. Fotherby, 1990, Contraception, 41, 533, 10.1016/0010-7824(90)90062-Z · doi:10.1016/0010-7824(90)90062-z
  6. Giangrande, 1999, Recent Prog Horm Res, 54, 291
  7. Grubb, 2003, Steroids, 68, 921, 10.1016/j.steroids.2003.09.001 · doi:10.1016/j.steroids.2003.09.001
  8. Maillard-Salin, 2000, Int J Pharm, 199, 29, 10.1016/S0378-5173(00)00357-4 · doi:10.1016/s0378-5173(00)00357-4
  9. Massai, 2001, Contraception, 64, 369, 10.1016/S0010-7824(01)00259-1 · doi:10.1016/s0010-7824(01)00259-1
  10. Musgrove, 1991, Mol Cell Biol, 11, 5032
  11. Nelson, 1996, J Reprod Med, 41, 391
  12. Noe, 1993, Contraception, 48, 548, 10.1016/0010-7824(93)90117-P · doi:10.1016/0010-7824(93)90117-p
  13. Odlind, 2002, Acta Obstet Gynecol Scand, 81, 482
  14. Oelkers, 1995, J Clin Endocrinol Metab, 80, 1816
  15. Oettel, 2001, Drugs Today, 37, 3
  16. Paris, 1983, Arzneimittelforschung, 33, 710
  17. Teichmann, 2003, Climacteric, 6, 17

Cited by

See all 362

Metadata

Authors
Sitruk-Ware, R.
Venue
Human Reproduction Update
Published
2005-11-16
Volume
12
Issue
2
Pages
169-178
ISSN
  • 1355-4786 (ISSN-L)
  • 1460-2369
OpenAlex
W2100560126
Cited by
362
References
54
FWCI
9.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New progestagens for contraceptive use. https://app.cochat.ai/papers/10.1093/humupd/dmi046
The paper
Sitruk-Ware, R. (2006). New progestagens for contraceptive use. Human Reproduction Update. https://doi.org/10.1093/humupd/dmi046

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.